Serum small RNA sequencing and miR-375 assay do not identify the presence of pure teratoma at post-chemotherapy retroperitoneal lymph node dissection by Murray, Matthew
Brief Correspondence
Serum Small RNA Sequencing and miR-375 Assay Do Not Identify
the Presence of Pure Teratoma at Postchemotherapy
Retroperitoneal Lymph Node Dissection
John T. Lafin a, Alexander P. Kenigsberg a, Xiaosong Meng a, Dreaux Abe a, Anna Savelyeva a,
Nirmish Singla a, Solomon L. Woldu a, Yair Lotan a, Ryan J. Mauck a, Cheryl M. Lewis b,
Vitaly Margulis a,c, Daniel Wong a, Liwei Jia d, Payal Kapur d, Lin Xu e, Ryan W. Speir f,
Gregory T. Chesnut g,h, A. Lindsay Frazier i, Douglas W. Strand a, Nicholas Coleman j,k,
Matthew J. Murray j,l, James F. Amatrudam,n,o, Aditya Bagrodia a,*
E U R O P E A N U R O L O G Y O P E N S C I E N C E 2 6 ( 2 0 2 1 ) 8 3 – 8 7
ava i lable at www.sc iencedirect .com
journa l homepage: www.eu-openscience.europeanurology.com
Article info
Article history:










Existing tumor markers for testicular germ cell tumor (TGCT) cannot detect the
presence of pure teratoma. Serum miRNAs have strong performance detecting
other subtypes of TGCT. Previous reports suggest high levels of miR-375 expression
in teratoma tissue. The purpose of this study was to explore the role of serum
miRNA, including miR-375, in detecting the presence of teratoma at postche-
motherapy retroperitoneal lymph node dissection (PC-RPLND).
We prospectively collected presurgical serum from 40 TGCT patients undergoing
PC-RPLND (21 with teratoma at RPLND and 19 with no evidence of disease). We
examined the utility of serum miR-375-3p and miR-375-5p by quantitative poly-
merase chain reaction, and searched for other putative serum miRNAs with small
RNA sequencing. The area under the receiver operating characteristic curve (AUC)
and univariate analyses were utilized to evaluate test characteristics and predictors
of teratoma.
Both serum miR-375-3p and miR-375-5p exhibited poor performance (miR-
375-3p: 86% sensitivity, 32% specificity, AUC: 0.506; miR-375-5p: 55% sensitivity,
67% specificity, AUC: 0.556). Teratoma at orchiectomy was the only predictor of PC-
RPLND teratoma. Small RNA sequencing identified three potentially discriminatory
miRNAs, but further validation demonstrated no utility. Our results confirm prior
reports that serum miR-375 cannot predict teratoma, and suggest that there may
not exist a predictive serum miRNA for teratoma.
Patient summary: We found that serum miR-375 cannot detect the presence of
teratoma at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).
We are also unable to find any other serum miRNAs predictive of pure teratoma at
PC-RPLND. Hence, the lack of a reliable circulating marker of teratoma remains a
critical clinical need.
© 2021 Published by Elsevier B.V. on behalf of European Association of Urology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).http://dx.doi.org/10.1016/j.euros.2021.02.003
2666-1683/© 2021 Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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beta-human chorionic gonadotropin, and alpha-fetoprotein
are a mainstay in the diagnosis and management of
testicular germ cell tumors (TGCTs). Recent work has
revealed that serum miRNAs exhibit greatly improved
performance over these STMs in detecting viable TGCT, but
neither conventional STMs nor TGCT-associated serum
miRNA is sensitive to pure teratoma [1]. Teratoma is a
common finding at postchemotherapy retroperitoneal
lymph node dissection (PC-RPLND), as 25–40% of resected
lymph nodes will contain teratoma and 40–50% will exhibit
no signs of residual disease [2]. Therefore, nearly half of
patients receiving PC-RPLND will do so unnecessarily. A
circulating marker sensitive to pure teratoma could preventFig. 1 – Serum miR-375 does not predict teratoma at PC-RPLND. Boxplots depic
and teratoma groups. Expression is displayed relative to the control group. Rec
performance of (B) miR-375-3p and (D) miR-375-5p. Area under the curve is d
characteristic curve; PC-RPLND = postchemotherapy retroperitoneal lymph nodthese unnecessary operations. Until recently, potential
targets for the detection of teratoma were elusive. A recent
genomic and epigenomic analysis of testicular tumors
demonstrated a promising high level of expression of miR-
375 among teratomas [3]. We first reported that serum miR-
375-3p was uninformative for teratoma in a small cohort
[4], and other recent studies investigating the utility of
circulating miR-375-3p have confirmed that it is not
predictive of teratoma [5]. We therefore set out to search
for other serum miRNAs predictive of pure teratoma at PC-
RPLND.
Following institutional review board approval, we
collected serum from 40 patients with 1-cm-diameter
retroperitoneal mass immediately prior to bilateral full-ting serum (A) miR-375-3p and (C) miR-375-5p expression in the control
eiver operating characteristic curve depicting discriminatory
isplayed on each graph. AUC = area under the receiver operating
e dissection.
E U R O P E A N U R O L O G Y O P E N S C I E N C E 2 6 ( 2 0 2 1 ) 8 3 – 8 7 85template PC-RPLND between 2016 and 2019. The pathology
of resected nodes was examined by experienced genitouri-
nary pathologists and classified as postpubertal-type
teratoma (21 cases total: 19 pure postpubertal teratoma,
one teratoma with yolk sac elements, and one teratoma
with yolk sac and embryonal carcinoma elements) or
control (19 cases total: seven benign, 11 fibrosis, and one
necrosis). Baseline characteristics of this population are
described in Supplementary Table 1. There were no
significant differences between the groups concerning
age, clinical stage, or conventional STM levels (Supplemen-
tary Table 2). We examined miR-375-3p (primary strand)
and miR-375-5p (passenger strand) levels in the serum
using an extraction and quantitative polymerase chain
reaction (qPCR) workflow similar to those described
previously for TGCT serum miRNA analysis (see the
Supplementary material). Final results were calculated
relative to the mean of all samples in the control group.
As expected, we found no difference in miR-375-3p
levels between the teratoma and control groups (Fig. 1A). At
a relative expression threshold of 0.6, as selected by
Youden’s J statistic, serum miR-375-3p demonstrated 86%Fig. 2 – Small RNA sequencing examination of serum miRNAs to detect teratom
hsa-miR-1299 fell outside the range of plot and is depicted as an arrow (log2FC
teratoma group over that in the control group. Blue dots are significantly diffe
miR-1299, (C) miR-1343-5p, and (D) miR-5689. PCR = polymerase chain reactiosensitivity and 32% specificity to detect residual teratoma.
Eighteen of 31 patients with miR-375-3p serum levels
above threshold actually harbored teratoma on final
pathology (58% positive predictive value). Nine patients
had negative miR-375-3p tests, of whom six had benign
pathology (67% negative predictive value). A receiver
operating characteristic analysis confirmed that serum
miR-375-3p lacked discriminatory capacity, with an area
under the receiver operating characteristic curve (AUC) of
0.506 (95% confidence interval [CI]: 0.32–0.69, p = 0.95;
Fig. 1B). We next examined serum miR-375-5p in a subset of
the patient pool (20 patients total, ten each in the teratoma
and control groups). Although miRNA passenger strands are
generally presumed to be rapidly degraded, previous
reports indicated detectable levels of miR-375-5p in the
serum [6]. Serum miR-375-5p also lacked any predictive
capacity for teratoma, with an AUC of 0.556 (95% CI: 0.30–
0.81, p = 0.68; Fig. 1C and 1D). At a relative expression
threshold of 1.16, sensitivity and specificity were calculated
as 55% and 67%, respectively. To ensure that the probes were
both sensitive and specific to their targets, we ran the assay
with a dilution series of known concentrations of miR-375-a. (A) Volcano plot of detected miRNAs in teratoma and control groups;
 = 21.92, –log10p = 13.2). Fold change is calculated as expression in the
rentially expressed miRNAs. (Quantitative PCR-based validation of (B)
n.
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exogenous spike-in, cel-miR-39-3p, remained unchanged
across samples. The probes targeting each strand of miR-
375 were found to specifically detect their target strand
(Supplementary Fig. 1). A univariate analysis revealed that
the only significant predictor of teratoma on final PC-RPLND
pathology was the presence of teratoma at original
orchiectomy specimen (p = 0.02; Supplementary Table 2).
We therefore conclude that neither miR-375-3p nor miR-
375-5p is a suitable serum marker of teratoma.
We next searched for other serum miRNAs predictive of
pure mature teratoma using small RNA sequencing. Out of
779 detected miRNAs, we identified 28 miRNAs as
differentially expressed (adjusted p < 0.1; Fig. 2A). Fourteen
of these were higher expressed in teratoma versus controls.
We selected three of these targets to validate by qPCR based
on expression levels, namely, miR-1299, miR-5689, and
miR-1343-5p. None of these targets were found to be
significantly different between the teratoma and control
groups by qPCR (Fig. 2B–D).
These results confirm previous findings that serum miR-
375-3p does not predict teratoma and demonstrate that
serum miR-375-5p does not predict teratoma at PC-RPLND.
Based on The Cancer Genome Atlas molecular profiling of
TGCT, miR-375 has been considered an attractive candidate
for a teratoma marker [7]. This conflicted with earlier reports
indicating that miR-375 expression was enriched in yolk sac,
but not teratoma, tissue [8,9]. We first examined this
discrepancy and reported the inability of serum miR-375-
3p to detect teratoma at primary RPLND, but the small sample
size required follow-up studies to confirm the result
[4]. Additional reports with more substantial sample sizes
examining both pre- and postchemotherapy patients have
since confirmed these results [5]. Lobo et al [5] identified
other serum miRNAs in their dataset, including miR-885-5p
and miR-448, with discriminatory capacity for teratoma.
Neither of these miRNAs was found to be differentially
expressed in our small RNA sequencing study. Nappi et al [10]
have very recently reported positive results regarding the
ability of plasma miR-375 in combination with miR-371a-3p
to predict teratoma. Although our results initially appear to
conflict with those of Nappi et al [10], their study found
limited utility of circulating miR-375 alone in detecting
teratoma in the validation cohort, in agreement with the
findings presented here and those referenced previously. The
ultimately negative results from our small RNA sequencing
data suggest that although serum miRNAs have performed
admirably in the detection of residual viable TGCT, perhaps
another avenue of investigation will be more fruitful in the
case of teratoma. However, caution must be taken when
interpreting these results, as the current study is limited by a
small sample size and the relatively low concentration of RNA
present in serum. Despite this, the lack of a reliable circulating
marker of teratoma remains a critical unmet clinical need.
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